Literature DB >> 24188048

Analgesic effects of Huwentoxin-IV on animal models of inflammatory and neuropathic pain.

Yu Liu, Zhe Wu, Dongfang Tang, Xiaohong Xun, Lichao Liu, Xianlei Li, Dongsong Nie, Yang Xiang, Jianming Yi, Jizu Yi1.   

Abstract

Huwentoxin-IV (HWTX-IV), a peptide with 35 amino acid residues, was discovered in the venom of spider Ornithoctonus huwena. The peptide had an inhibitory effect on a tetrodotoxin-sensitive (TTX-S) sodium channel with highly sensitive to Nav1.7, an attractive target for pain release therapy. In this study we further demonstrated the analgesic effects of HWTX-IV using mouse and rat as an inflammatory pain model and/or a neuropathic pain models. In the both cases, the analgesic effects of the peptide were dose-dependent, and statistically significant. In the inflammatory model, 100 µg/kg of HWTX-IV produced an efficient reversal of hyperalgesia up to 63.6% after injection of formalin in rats with the efficiency equivalent to that of morphine at 50 µg/kg, and 200 µg/kg of HWTX-IV produced protective effect up to 55.6% after injection of acetic acid with the efficiency equivalent to that of morphine at 100 µg/kg. In the spinal nerve model, the peptide produced the longer and higher reversal effect on allodynia than Mexiletine. These results demonstrated that HWTX-IV released efficiently the acute inflammatory pain and chronic neuropathic pain in these animals, suggesting that HWTX-IV was a potential and efficient candidate for further clinical drug development against inflammatory and neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24188048     DOI: 10.2174/09298665113206660119

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  13 in total

Review 1.  Sodium channels and pain: from toxins to therapies.

Authors:  Fernanda C Cardoso; Richard J Lewis
Journal:  Br J Pharmacol       Date:  2017-09-02       Impact factor: 8.739

2.  Synthetic Analogues of Huwentoxin-IV Spider Peptide With Altered Human NaV1.7/NaV1.6 Selectivity Ratios.

Authors:  Ludivine Lopez; Jérôme Montnach; Barbara Oliveira-Mendes; Kuldip Khakh; Baptiste Thomas; Sophia Lin; Cécile Caumes; Steven Wesolowski; Sébastien Nicolas; Denis Servent; Charles Cohen; Rémy Béroud; Evelyne Benoit; Michel De Waard
Journal:  Front Cell Dev Biol       Date:  2021-12-20

3.  GpTx-1 and [Ala5 , Phe6 , Leu26 , Arg28 ]GpTx-1, two peptide NaV 1.7 inhibitors: analgesic and tolerance properties at the spinal level.

Authors:  Chao Chen; Biao Xu; Xuerui Shi; Mengna Zhang; Qinqin Zhang; Ting Zhang; Weidong Zhao; Run Zhang; Zilong Wang; Ning Li; Quan Fang
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

4.  Pharmacological characterization of venoms from three theraphosid spiders: Poecilotheria regalis, Ceratogyrus darlingi and Brachypelma epicureanum.

Authors:  Alejandro García-Arredondo; Luis Rodríguez-Rios; Luis Fernando Díaz-Peña; Ricardo Vega-Ángeles
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2015-06-17

5.  The structure, dynamics and selectivity profile of a NaV1.7 potency-optimised huwentoxin-IV variant.

Authors:  Sassan Rahnama; Jennifer R Deuis; Fernanda C Cardoso; Venkatraman Ramanujam; Richard J Lewis; Lachlan D Rash; Glenn F King; Irina Vetter; Mehdi Mobli
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

Review 6.  The NaV1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons.

Authors:  Tânia C Gonçalves; Evelyne Benoit; Michel Partiseti; Denis Servent
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

Review 7.  Structure-Function and Therapeutic Potential of Spider Venom-Derived Cysteine Knot Peptides Targeting Sodium Channels.

Authors:  Fernanda C Cardoso; Richard J Lewis
Journal:  Front Pharmacol       Date:  2019-04-11       Impact factor: 5.810

8.  Voltage-Gated Sodium Channel Modulation by a New Spider Toxin Ssp1a Isolated From an Australian Theraphosid.

Authors:  Yashad Dongol; Phil M Choi; David T Wilson; Norelle L Daly; Fernanda C Cardoso; Richard J Lewis
Journal:  Front Pharmacol       Date:  2021-12-24       Impact factor: 5.810

9.  Selective Closed-State Nav1.7 Blocker JZTX-34 Exhibits Analgesic Effects against Pain.

Authors:  Xiongzhi Zeng; Pengpeng Li; Bo Chen; Juan Huang; Ren Lai; Jingze Liu; Mingqiang Rong
Journal:  Toxins (Basel)       Date:  2018-02-02       Impact factor: 4.546

10.  Engineering Gain-of-Function Analogues of the Spider Venom Peptide HNTX-I, A Potent Blocker of the hNaV1.7 Sodium Channel.

Authors:  Yunxiao Zhang; Qiuchu Yang; Qingfeng Zhang; Dezheng Peng; Minzhi Chen; Songping Liang; Xi Zhou; Zhonghua Liu
Journal:  Toxins (Basel)       Date:  2018-09-04       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.